source
- Otsuka and Ionis report ALS drug ulefnersen meets primary endpoint in phase 3 trialOtsuka and Ionis have completed the Fusion phase 3 trial of ulefnersen, an RNA‑targeted therapy for ALS patients with mutations in the FUS gene. The study enrolled 89 participants, with 73 forming…
- Novartis licenses preclinical radioligand from China's BoomRay in up to $900 million dealNovartis has expanded its radiopharmaceutical pipeline by signing a licensing agreement with Chinese biotech BoomRay Therapeutics. The deal could be worth up to $900 million, including an upfront…